The use of biologic agents in pediatric inflammatory bowel disease

Current Opinion in Pediatrics

Volumn 24, Issue 5, 2012, Pages 609-614

  Yang, Linda S ^a   Alex, George ^a,b   Catto Smith, Anthony G ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Adalimumab; immunosuppressants; infection; infliximab; malignancy; pediatrics

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CYCLOSPORIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALGORITHM; CROHN DISEASE; DEMYELINATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FOLLICULAR LYMPHOMA; GUILLAIN BARRE SYNDROME; HEPATITIS B; HEPATOSPLENIC T CELL LYMPHOMA; HERPES ZOSTER; HISTOPLASMOSIS; HODGKIN DISEASE; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; LONG TERM CARE; MAINTENANCE THERAPY; NEOPLASM; NEUROTOXICITY; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PARASITOSIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; T CELL LYMPHOMA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL AGENTS; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; EVIDENCE-BASED MEDICINE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFANT; MALE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866383143     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3283574154     Document Type: Review

References (51)

1. Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011; 17:423-439.
2. Schildkraut V, Alex G, Cameron D, et al. Sixty-year study of incidence of childhood ulcerative colitis finds eleven-fold increase beginning in 1990s. Inflamm Bowel Dis 2012. doi: 10.1002/ibd.229972. [Epub ahead of print]
3. Sprakes MB, Ford AC, Warren L, et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis 2012; 6:143-153.
4. Magro F, PortelaF.Managementofinflammatory bowel disease with infliximab and other antitumor necrosis factor alpha therapies. BioDrugs 2010; 24 (Suppl. 1):3-14.
5. Breda L, Del Torto M, De Sanctis S, Chiarelli F. Biologics in children's autoimmune disorders: efficacy and safety. Eur J Pediatr 2011; 170:157-167.
6. Marji JS, Marcus R, Moennich J, Mackay-Wiggan J. Use of biologic agents in pediatric psoriasis. J Drugs Dermatol 2010; 9:975-986.
7. Rigopoulos D, Korfitis C, Gregoriou S, Katsambas AD. Infliximab in derma-tological treatment: beyond psoriasis. Expert Opin Biol Ther 2008; 8:123-133.
8. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010; 11:180-210.
9. Hyams JS, Wilson DC, Thomas A, et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr 2007; 44:185-191.
10. Bickston SJ, Muniyappa K. Natalizumab for the treatment of Crohn's disease. Expert Rev Clin Immunol 2010; 6:513-519.
11. De Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis 2011; 18:985
12. Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010; 138:2282-2291.
13. Mahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011; 106:214-223.
14. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenter-ological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastro-enterology 2006; 130:935-939.
15. Sandhu BK, Fell JM, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010; 50:S1-S13.
16. Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastro-enterol Hepatol 2011; 10:391-399.
17. McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children and adolescents. J Clin Gastroenterol 2008; 42:875-879.
18. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476.
19. Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and-2 extension studies. Inflamm Bowel Dis 2012; 18:201-211.
20. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcera-tive colitis. Gastroenterology 2011; 141:1194-1201.
21. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010; 16:338-346.
22. Sciaudone G, Pellino G, Guadagni I, Selvaggi F. Infliximab avoiding colectomy and maintaining remission in pediatric immunosuppressive-naive ulcerative colitis achieving remarkable mucosal healing. Panminerva Med 2010; 52:91-92.
23. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126:451-459.
24. Risques RA, Lai LA, Brentnall TA, et al. Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology 2008; 135:410-418.
25. Jakobsen C, Bartek J Jr, Wewer V, et al. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease-a population-based study. Aliment Pharmacol Ther 2012; 34:1217-1224; Erratum appears in Aliment Pharmacol Ther 2012; 35:864.
26. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63:433-442; quiz 464.
27. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132:863-873; quiz 1165-1166.
28. Crombe V, Salleron J, Savoye G, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis 2011; 17:2144-2152.
29. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371:660-667.
30. Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis 2012. doi: 10.1002/ibd.22925. [Epub ahead of print]
31. Kim MJ, Lee JS, Lee JH, et al. Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing 'top-down' and 'step-up' strategies. Acta Paediatr 2011; 100:451-455.
32. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007; 13:424-430.
33. De Iudicibus S, Stocco G, Martelossi S, et al. Genetic predictors of gluco-corticoid response in pediatric patients with inflammatory bowel diseases. J Clin Gastroenterol 2011; 45:e1-e7.
34. Dubinsky MC, Mei L, Friedman M, et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2010; 16:1357-1366.
35. Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology 2003; 124:1140-1145.
36. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the longterm efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601-608.
37. Candon S, Mosca A, Ruemmele F, etal. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol 2006; 118:11-19.
38. Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004; 38:502-508.
39. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56:1226-1231.
40. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59:1363-1368.
41. Gouldthorpe O, Catto-Smith AG, Alex G. Biologics in paediatric Crohn's disease. Gastroenterol Res Pract 2011; 2011:287574.
42. Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010; 62:2517-2524.
43. Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011; 106:2146-2153.
44. Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis 2010; 4:511-522.
45. Cucchiara S, Escher JC, Hildebrand H, et al. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr 2009; 48:257-267.
46. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9:36-41; e31.
47. Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009; 104:3042-3049.
48. Russell RK, Wilson ML, Loganathan S, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33:946-953.
49. Castineiras I, Fernandez-Diaz L, Juarez Y, Lueiro M. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies. J Dermatol 2012. doi: 10.1111/j.1346-8138.2011.01499. x. [Epub ahead of print]
50. Hamilton MJ, Snapper SB, Blumberg RS. Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance. J Gastroenterol 2012; 47:1-8.
51. Malik T, Mannon P. Inflammatory bowel diseases: emerging therapies and promising molecular targets. Front Biosci (Schol Ed) 2012; 4:1172-1189.